Radiopharm Theranostics LTD (RADX) — SEC Filings

Overview

Radiopharm Theranostics LTD (RADX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 16, 2026: Radiopharm Theranostics Ltd. announced on April 16, 2026, the completion of enrollment for its Phase 2b trial of RAD 101. This marks a significant milestone in the development of their radiopharmaceutical.

Sentiment Summary

Across 5 filings, the sentiment breakdown is: 2 bullish, 3 neutral. The dominant filing sentiment for Radiopharm Theranostics LTD is neutral.

Filing Type Overview

Radiopharm Theranostics LTD (RADX) has filed 1 3, 4 6-K with the SEC between Mar 2026 to Apr 2026.

Recent Filings (5)

• Radiopharm Theranostics Completes RAD 101 Phase 2b Trial Enrollment — 6-K · Apr 16, 2026 Risk: medium
  Radiopharm Theranostics Ltd. announced on April 16, 2026, the completion of enrollment for its Phase 2b trial of RAD 101. This marks a significant milestone in
• 6-K Filing — 6-K · Apr 8, 2026
• Radiopharm Theranostics Signs Supply Deal with Siemens — 6-K · Apr 7, 2026 Risk: medium
  Radiopharm Theranostics Ltd. announced on April 7, 2026, a clinical supply agreement with Siemens for its RAD101 product. This agreement is a significant step i
• Radiopharm Theranostics Ltd Files Initial Ownership Statement — 3 · Apr 2, 2026 Risk: low
  Radiopharm Theranostics Ltd, an issuer, filed a Form 3 on April 1, 2026, indicating an initial statement of beneficial ownership of securities. The filing relat
• Radiopharm RAD101 Phase 2B Hits 90% Primary Endpoint — 6-K · Mar 24, 2026
  Radiopharm Theranostics Ltd filed a 6-K on March 24, 2026, announcing positive interim Phase 2B data for its drug RAD101. The filing states that 90% of patients

Frequently Asked Questions